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BACKGROUND The presence of acute renal injury (AKI) enhances
morbimortality after surgical aortic valve. However, the risk of peri-
procedural AKI and its association with outcomes after transcatheter
aortic valve replacement (TAVR) is still incompletely understood. This
prospective observational study aims to determine the incidence of
AKI, its predictors and impact on 30-days and 1-year mortality.
METHODS We assessed data from 225 consecutive patients with se-
vere symptomatic aortic stenosis submitted to TAVR between January
2009 and February 2015 on two tertiary cardiologic centers, conducted
by the same heart team. All patients used an ionic, low-osmolar, low-
viscosity contrast. Kidney injury was deﬁned according to VARC
(Valve Academic Research Consortium) criteria, following AKIN sys-
tem, and analyzing data until the seventh day post-procedure. Three
patients were excluded due to death during the procedure, consid-
ering those deaths not related to renal dysfunction. One patient was
excluded due to incomplete data. The remaining 221 patients
comprised the population of the current analysis separated in two
groups: AKI group (group 1) and non-AKI group (group 2). Follow-up
was performed on 30 days and after one year.
RESULTS At baseline, mean age was 82.24  6.78 years, 53% women,
transfemoral access 75.6%. Fifty two patients (23.5%) developed AKI
until seventh day of procedure. Groups 1 and 2 were similar, except
for EuroSCORE II (8.66%  5.64% vs 7.34%  8.58%, p ¼ 0.02) and
glomerular ﬁltration rate (GFR) (39.59 ml/min.1.73m2  13.62 vs. 48.49
 19.6, p ¼ 0.002). Overall 30 days-mortality and 1-year mortality was
6.3% and 14.0%, respectively. Both 30-day mortality (23.1% vs 1.2%,
p < 0.001) and 1-year mortality (44.2% vs 4.7%, p< 0.001) were higher
in group 1. In multivariable-adjusted models, the only independent
predictor for AKI after TAVR was baseline GFR [hazard ratio (HR) 1.37,
CI 95% 1.08-1.77, p ¼ 0.01]. Regarding long term follow-up, AKI (HR
19.86, CI 95% 7.31-53.98, p <0.001) and COPD (HR 3.14, IC 95% 1.05-
9.40, p ¼ 0.04) were independent risk factors for 1-year mortality,
whilst hypertension (HR 0.269, 0.09-0.80, p ¼ 0.01) was shown to be
protective for long term mortality.
CONCLUSIONS In this TAVR sample, baseline GFR was the only in-
dependent predictor of AKI, and patients who developed it had
signiﬁcantly higher mortality at 30 days and 1 year. Acute renal
impairment was the strongest risk factor for mortality and adverse
cardiovascular events that provided risk information beyond the
traditional scores, as EuroSCORE II and STS. Careful identiﬁcation of
risk factors and development of more suitable risk scores is essential.
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BACKGROUND Following transcatheter aortic valve Implantation
(TAVI), patients are usually monitored by telemetry for a few days.
However, there is currently no consensus on the duration of telem-
etry, and some patients may not require telemetry at all. In the pre-
sent study, we sought to evaluate how the postprocedural ECG
determines the need for pacemaker implantation and optimal dura-
tion of telemetry monitoring.
METHODS Patients without a permanent pacemaker undergoing TAVI
at two centers in Switzerland were investigated. ECGs at baseline and
post TAVI were analyzed to identify atrioventricular and interven-
tricular conduction disorders. A normal ECG was deﬁned as a QRS
width < 120 ms and a PQ time < 200 ms. The occurrence and timing of
high degree atrioventricular block (AVB) and the need for Implanta-
tion of a permanent pacemaker was recorded.
RESULTS A total of 537 patients underwent TAVI with either the
CoreValve (n ¼ 265) or the SAPIEN XT or SAPIEN 3 (n¼ 272). None of
the patients with a normal postprocedural ECG developed high degree
atrioventricular block (AVB) or required implantation of a permanent
pacemaker. Patients with a narrow QRS but impaired AV conduction
required a pacemaker in 6/58 (9.4%), and heart block occurred as late
as 3 days post procedure. Patients with a wide QRS and normal AV
conduction required a pacemaker in 17/154 (11.0%) and heart block
occurred up to 2 days post procedure. Patients with a wide QRS and
impaired AV conduction required a pacemaker in 24/61 (39.3%) and
heart block occurred as late as 5 days post procedure. Almost all pa-
tients (60/61, 98.4%) with a complete heart block post procedure
required implantation of a permanent pacemaker.
CONCLUSIONS The postprocedural ECG was predictive of the
required duration of telemetry monitoring regardless of the type of
valve implanted. Patients with a normal ECG post TAVI did not
develop high-degree heart block and did not require implantation of a
permanent pacemaker. Such patients do not require telemetry and
may be candidates for early discharge. Telemetry monitoring of 2 days
should be considered for patients with wide QRS post TAVI. Patients
with impaired AV conduction post TAVI required up to 5 days of
telemetry monitoring. The ﬁndings of this study may help to improve
in-hospital management of TAVI patients and reduce costs associated
with this procedure.
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BACKGROUND The SAPIEN 3 (Edwards Lifescience) balloon-expand-
able valve incorporates a paravalvular sealing system, an active 3-
dimensional coaxial positioning catheter, and is compatible with a 14-
F expandable sheath. These characteristics provide a theoretical su-
periority over previous device, including feasibility of TAVR (trans-
catheter aortic valve replacement) in a broader range of patients,
better accuracy in valve positioning and less paravalvular regurgita-
tion. We aimed to evaluate short-term outcomes in TAVR patients
who beneﬁted from 3rd generation SAPIEN 3 valve implantation and
to compare these results to those obtained with the earlier generation
SAPIEN XT device.
METHODS This single center prospective study included all patients
who underwent TAVR with balloon-expandable SAPIEN valve
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PIEN XT (Jan 2013-September 2014) and SAPIEN 3 (October 2014-
March 2015). All patients presented severe aortic stenosis who were
refused for conventional surgery. Procedure success, clinical out-
comes and peri-procedural complications were prospectively assessed
according to the Valve Academic Research Consortium (VARC)-2
criteria.
RESULTS N¼142 consecutive patients who underwent TAVR using
SAPIEN device were included in the study (n¼76 SAPIEN XT and n¼66
SAPIEN 3). There was no difference between groups regarding age,
Euroscore, gender, previous medical history and left ventricle ejection
fraction. However, SAPIEN 3 patients had a higher prevalence of pe-
ripheral arterial disease (65.2 vs. 36.8%, p¼0.001) and ilio-femoral axis
calciﬁcations on scanner (47.9 vs; 26.5 %, p¼0.008) than the others.
Moreover, SAPIEN 3 patients had a smaller aortic valve area than
SAPIEN-XT subjects (0.670.9 vs 0.76  0.14 cm2/m2, p¼0.007), yet
there was no signiﬁcant difference in aortic annulus diameter (254.5
vs 23.82 mm, p¼ns). TAVR was performed through transfemoral
access in 96% in both groups. Device implantation success rate was
higher (100% vs. 90%, p¼0.002) in the SAPIEN 3 than in the SAPIEN-
XT group .The prevalence of moderate to severe paravalvular leak was
lower in SAPIEN 3 than in SAPIEN-XT patients (0% vs 9.2%, p¼0.01).
We observed fewer hemorrhagic events in the SAPIEN 3 group than in
the other, as assessed by the lower incidence of life-
threatening þmajor bleeding events (0% vs 9.2%, p¼0.01). There was
no difference regarding the 30-days rate of MACCE (major adverse
cardiovascular & cerebrovascular events) between patients, including
no difference in terms of death (3% vs. 5%), stroke (3% vs. 2.6%) and
major vascular complications (6% vs. 13.1%). Finally, the rate of per-
manent pacemaker implantation were comparable in both groups
(10.6 vs. 14.5%, p¼0.49).
CONCLUSIONS The use Edwards SAPIEN 3 allows TAVR in patients
with more severe peripheral artery disease. Moreover, this device
provides excellent short-term outcome and lower rates of para-
valvular regurgitations compared to the previous generation SAPIEN-
XT valve.
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BACKGROUND Prospective randomized trials have demonstrated
that transcatheter aortic valve replacement (TAVR) is an effective
alternative to surgical aortic valve replacement (SAVR) for patients
with severe aortic stenosis at increased surgical risk, but reasons why
left ventricular (LV) mass regresses more rapidly and to a greater
extent after SAVR than TAVR despite a higher AV gradient after SAVR
is unknown. We sought to determine why LV mass regression is
greater after SAVR.
METHODS Baseline and serial echocardiography studies of patients
randomized to SAVR with a bioprosthetic valve vs TAVR with a self-
expanding CoreValve were analyzed by an Echo Core Lab blinded toTable. Echocardiographic Parameters by Treatment Over Time
Baseline Discharge
TAVR SAVR TAVR SAVR TA
LVEDD (cm) 4.97  0.63 (347) 5.01  0.64 (311) 4.91  0.64 (303) 4.81  0.65 (225) 4.99  0
IVST (mm) 11.97  2.35 (341) 12.00  2.07 (309) 12.26  2.41 (295) 11.99  1.94 (219) 11.79  2
PWT (mm) 11.19  1.98 (338) 11.24  1.95 (311) 11.39  2.05 (297) 11.45  1.73 (216) 11.05  1
SV by 2DE (mL) 70.42  27.21 (185) 72.64  27.04 (171) 70.36  24.48 (168) 58.93  21.10 (122) 74.36  2
Doppler SV (mL) 75.77  23.49 (349) 74.96  20.16 (307) 74.89  19.90 (335) 63.35  19.71 (256) 77.93  2
LV mass (gm) 226.07  72.54 (333) 227.45  65.02 (304) 226.78  72.98 (291) 215.08  59.02 (212) 221.19  6
LV mass index (gm/m2) 122.45  35.73 (333) 123.54  33.55 (304) 122.82  35.97 (291) 116.43  28.94 (212) 119.45  3
 Moderate AR (%) 5.2% (20/385) 6.1% (21/346) 9.1% (33/363) 1.0% (3/306) 10.0% (treatment and outcomes. Echocardiography measurements including
AV gradient were performed according to established guidelines and
LV mass was calculated using the formula of Devereaux et al: 0.83 x
([(LVEDD þ LVPWT þ IVS)3 – [(LVEDD)3]) þ0.6. LVEDD¼LV end-dia-
stolic dimension, PWT¼posterior wall thickness, and
IVST¼interventricular septal thickness.
RESULTS Echo data were available in 389 TAVR and 353 SAVR pa-
tients (Table). LVEDD, PWT, IVS, LV mass, and SV were similar in
TAVR and SAVR at baseline. These variables were unchanged at
discharge with TAVR. However, after SAVR at discharge, LV mass
decreased from 227.4565.02 to 215.0859.02 gm (P¼0.002), and
LVEDD from 5.010.64 to 4.810.65 cm (P<0.0001), although PWT
and IVS were unchanged. 2D derived stroke volume (SV) also declined
at discharge from 72.6427.04 mL to 58.9321.10 mL (P¼0.01) after
SAVR, but not after TAVR (70.4227.21 mL to 70.3624.48 mL;
P¼0.46). Similar changes were observed with Doppler derived SV. At 1
year, LV mass, SV and LVEDD remained smaller following SAVR vs.
TAVR, a difference that persisted after exclusion of those with 
moderate aortic regurgitation (AR).
CONCLUSIONS Greater LV mass regression after SAVR is due to
smaller post-operative LVEDD associated with lower SV after SAVR
than TAVR. Further study is needed to identify the reasons for
reduced SV after SAVR.
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BACKGROUND This is the ﬁrst study comparing outcomes after
transfemoral transcatheter aortic valve replacement (TAVR) with
Symetis ACURATE (ACT) - a new device -, Medtronic CoreValve (MCV)
and Edwards Sapien XT (SXT).
METHODS We prospectively evaluated patients with severe aortic
stenosis undergoing transfemoral TAVR at two centers coordinated by
the same Heart Team. Study objectives were echocardiography ﬁnd-
ings and Valve Academic Research Consortium (VARC) at 30 days.
RESULTS We evaluated 162 patients (ACT n¼48, MCV n¼57, SXT
n¼57). Baseline clinical and imaging features are resumed in Table 1.
Immediately after the procedure, Device Success were lower with
MCV (97.9% vs 86% vs 94.7%; p¼0,049), as well as Aortic Valve Area
(1.900.26 vs 1.810.32 vs 2.010.28; p¼0.002), with no differences in
Mean Gradient (p¼0.752) or Moderate/Severe Aortic Regurgitation
(p¼0.272). At 30 days, there were no signiﬁcant difference in all-cause
mortality (p¼0.298), cardiovascular mortality (p¼0.222), myocardial
infarction (p¼0.776) and stroke (p¼0.999). Additionally, no differ-
ences were found in major vascular complications (p¼0.594), life-
threatening bleeding (0.378) and stage 3 acute kidney injury1 Month 6 Months 1 Year
VR SAVR TAVR SAVR TAVR SAVR
.65 (318) 4.74  0.66 (247) 5.01  0.67 (279) 4.74  0.63 (206) 4.98  0.66 (262) 4.80  0.56 (190)
.12 (312) 11.68  2.09 (245) 11.50  2.32 (269) 11.62  1.97 (205) 11.35  2.17 (257) 11.48  2.37 (189)
.83 (307) 10.96  1.79 (237) 10.57  1.82 (266) 11.12  1.87 (199) 10.51  1.89 (255) 10.21  1.96 (189)
4.59 (173) 59.76  20.71 (123) 72.37  22.04 (141) 66.34  22.74 (100) 73.45  23.81 (118) 71.45  22.01 (81)
3.53 (349) 67.59  20.29 (282) 79.69  23.33 (297) 73.57  20.35 (224) 79.56  22.90 (278) 74.78  21.35 (206)
9.63 (303) 200.22  58.38 (232) 213.07  65.74 (260) 201.79  57.83 (196) 207.83  64.02 (247) 192.71  58.54 (185)
3.88 (303) 108.83  29.31 (232) 114.23  30.74 (260) 108.67  26.81 (196) 111.35  29.85 (247) 102.80  27.99 (185)
36/359) 1.3% (4/308) 11.3% (36/318) 1.6% (4/252) 7.1% (21/297) 1.3% (3/223)
